Study S001789

A Phase 3, Randomized, Active Comparator, Double-Blind, Multi-Center Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Sitagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes

ClinicalTrials.gov record

Registration

Registration: NCT01455909
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: WITHDRAWN
Enrollment: 0
Start: 2013-02
Primary completion: 2014-07
Lead sponsor: Intarcia Therapeutics
Conditions: Type 2 Diabetes
Interventions: DRUG:ITCA 650 60 mcg/day; DRUG:sitagliptin
Results posted: FALSE

Registered primary outcomes

Change in HbA1c [39 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.